Monitoring high-risk patients for chemotherapy-related cardiotoxicity: A retrospective analysis

Figure 1 Distribution of different drug classes among patients with and without cardiotoxicity. The X-axis represents drug classes, while the Y-axis shows the percentage of patients exposed to each category. Blue bars correspond to patients without cardiotoxicity, whereas orange bars indicate those with cardiotoxicity. The highest prevalence was observed in the "Anthracyclines & Antimetabolites (Cytarabine)" group, with 51% of patients without cardiotoxicity and 53% with cardiotoxicity. Conversely, "Antimetabolites" have the lowest representation, with 8% in the non-cardiotoxicity group and 6% in the cardiotoxicity group.